Structure Therapeutics (GPCR) announced that it has initiated a first-in-human Phase 1 clinical study of ACCG-2671, the company’s lead oral small molecule amylin receptor agonist for the treatment of obesity. ACCG-2671 was designed via the company’s next generation structure-based drug discovery platform to harness the established metabolic benefits of amylin biology in an oral, once-daily small molecule, with the potential to improve scalability, combinability, and patient access.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Structure Therapeutics price target raised to $125 from $120 at Morgan Stanley
- Structure Therapeutics price target raised to $120 from $87 at Citizens
- Structure Therapeutics price target raised to $125 from $79 at Jefferies
- Structure Therapeutics Announces $650 Million Public Offering
- Structure Therapeutics 8.5M share Spot Secondary priced at $65.00